Articles tagged with Vaccine Development
Researchers at UCI create a new method to rapidly discover antigens for vaccines, enabling the expression of hundreds of proteins in just one week. This technique addresses the bottleneck in processing large amounts of data from genome sequences, allowing for faster vaccine development and improved safety.
The Global HIV/AIDS Vaccine Enterprise has launched a scientific strategic plan to address major roadblocks in HIV vaccine development and proposes an innovative collaborative model for researchers worldwide. The plan aims to harness new opportunities, including an expanded pipeline of HIV vaccine candidates and improved animal models.
A vaccine against cervical cancer has been developed by Dutch researcher Laura Bungener. The vaccine induces an immune response to proteins from human papillomavirus (HPV), rendering it harmless and preventing the growth of tumors. Laboratory animals with existing tumors could also be treated with this vaccination.
The NIAID human clinical vaccine trial tests an experimental vaccine composed of a small circular piece of DNA encoding the viral spike protein. The trial aims to assess the vaccine's safety and immune-stimulating effects in people, with results expected to inform future vaccine development.
The Imperial College London team, led by Dr. Danny Altmann, is developing new vaccines against anthrax and other bio-weapons using state-of-the-art technologies. The research will also contribute to a better understanding of emerging infectious diseases and the development of effective diagnostics and treatments.
A recent UK study published in The Lancet has found no association between the MMR vaccine and the development of autism or pervasive developmental disorders. Researchers analyzed data from over 1,300 cases and 4,469 controls, concluding that vaccination did not increase the risk of these conditions.
Researchers at UCI are working on a vaccine against melioidosis, caused by B. pseudomallei, a bacterium that thrives in water and can cause severe pneumonia and septic shock. The development of a safe and effective vaccine is crucial to blunt bioterrorism threats.
A phase 1 vaccine trial has demonstrated that a group A streptococcal vaccine appears safe and well-tolerated, inducing immune responses capable of conferring protection against multiple strains. The study's findings suggest that a specific dose and schedule may be effective in preventing group A streptococcal infections.
A novel protein vaccine candidate has demonstrated full protection against a lethal aerosol challenge with ricin toxin in mice, offering a promising solution to bioterrorism threats. The vaccine, RTA 1-33/44-198, was designed using molecular modeling and protein engineering techniques.
A new breed of vaccine-producing plants is being developed to combat global health issues, including cholera and diarrhea. The innovative technology uses minimal processing to yield heat-stable vaccines for oral delivery.
A new triple-vaccine strategy has been shown to stimulate a strong HIV-specific immune response in monkeys, demonstrating its potential as an improved method of protection against the virus. The approach uses a series of three vaccines that build on each other to generate a stronger immune response than might otherwise be possible.
Researchers have developed an intranasal SARS vaccine that protects African green monkeys from infection with a single dose, delivering the vaccine directly into the respiratory tract. The vaccine targets the SARS spike protein and induces neutralizing antibodies against the virus.
Researchers found thimerosal exposure in mice led to autism-like behaviors, including abnormal responses to environments and brain abnormalities. The study suggests a potential connection between genetic susceptibility and environmental triggers for autism, highlighting the need for further research and intervention strategies.
Researchers at Saint Louis University have demonstrated that the smallpox vaccine candidate LC16m8 protects mice from a virus related to smallpox when delivered via aerosol. The study aims to develop a safer smallpox vaccine for bioterrorism threats.
Researchers have developed a new vaccine strategy using live, crippled Salmonella bacteria that stimulate immunity to multiple pathogens. The vaccine protected mice 100% against lethal doses of both S. typhimurium and Listeria monocytogenes.
The NIAID-licensed rotavirus vaccine has been developed to combat severe diarrhea in infants and young children worldwide. The vaccine has shown promise in reducing the number of deaths caused by rotavirus infections, particularly in developing countries where access to effective treatments is limited.
A new investigational anthrax vaccine is being tested in a phase II human study at Saint Louis University. The vaccine aims to provide better protection, an improved safety profile and a simpler dosing schedule.
Researchers develop two SARS vaccine candidates that effectively protect mice from infection, utilizing different technologies to stimulate the immune system. The vaccines target the S protein, a key component of the coronavirus responsible for initiating infection.
The collaboration aims to improve the BCG vaccine, which offers protection against serious forms of TB in childhood but loses efficacy over time. A new vaccine is crucial to combating the disease that kills over two million people globally per year.
Researchers have successfully tested a new plague vaccine in a real-world mouse model, showing promising results. The vaccine was tested in a natural transmission setting, where infected fleas fed on vaccinated mice, and showed protection against the disease.
A consortium has launched a programme to develop a TB vaccine, with the Max Planck Institute for Infection Biology developing a highly promising candidate. The vaccine aims to improve upon the existing BCG vaccine, which lacks effectiveness against pneumotuberculosis.
A new TB vaccine, rBCG30, is being tested in a human clinical trial to assess its safety and immune response. The vaccine, developed by Dr. Marcus Horwitz and his team at UCLA, has shown promise in preclinical trials and could potentially reduce the TB disease burden worldwide.
Researchers found that even delayed responses to smallpox cases could still contain the outbreak through targeted vaccination and isolation. Surveillance and containment were more effective than mass vaccination in controlling the spread of smallpox.
Researchers are testing a new flu vaccine that delivers the vaccine in the nose to observe differences in immune system reactions. The study aims to improve immunity in the respiratory tract for all pathogens, with implications for biodefense.
The Gates Foundation has committed $82.9 million to develop new tuberculosis vaccines, with the goal of creating a more effective vaccine within 10 years. The grant will support research in three major areas: vaccine trials, improved animal models, and next-generation vaccines.
The National Vaccine Advisory Committee recommends strengthening routine vaccine supplies by increasing funds for stockpiles, supporting regulatory agencies, and improving communication. The committee also highlights the need for increased investment in vaccine manufacturing facilities and development of new vaccines to sustain supply.
Researchers at USAMRIID have developed Ebola virus-like particles (VLPs) that induce both cell-mediated and humoral immunity in mice, providing 100% protection against lethal challenge. The VLPs, resembling infectious viral particles without genetic material, offer a promising vaccine platform for Ebola and other viruses.
St. Jude experts highlight US vaccine production inadequacies and antiviral drug scarcity in responding to an outbreak, emphasizing the need for new technologies, international cooperation, and rapid testing.
The IU School of Medicine and Merck have partnered to establish a vaccination training program in Kenya. The program aims to enhance immunization infrastructure and reduce infant morbidity and mortality due to preventable diseases.
Researchers at Georgia Tech have made significant progress in developing hollow and solid microneedles that can deliver proteins, nanoparticles, and large molecules through the skin with minimal pain. The technology has potential applications in treating various diseases, including diabetes.
A Phase II clinical study of TP10 found that the complement inhibitor significantly reduced heart attacks and death in male patients undergoing open heart surgery. The study showed a significant decrease in composite endpoints for death, myocardial infarction, and prolonged intubation in males treated with TP10.
Researchers developed vaccines based on human and chimpanzee adenoviruses to protect newborns against viral diseases. These oral vaccines have the potential to be effective even with waning maternal antibodies, offering a crucial solution for infants in developing countries.
A South African clinical trial showed a significant reduction in pneumococcal disease incidence with the conjugate vaccine, resulting in a 5% decrease among all children and a 6% decrease among HIV-infected children. The study demonstrates the vaccine's effectiveness in preventing invasive pneumococcal disease and saving lives.
Four research organizations will receive funding to develop promising HIV vaccine candidates using DNA vaccines, virus vector vaccines, subunit vaccines, and virus-like particle vaccines. Researchers aim to induce strong cellular and antibody immune responses in animal models.
The NIH has awarded $85 million to five cooperative centers for translational research on human immunology and biodefense. Researchers will develop new ways to analyze immune cells and use imaging technologies to study vaccine responses, aiming to strengthen the immune system against diseases.
A malaria vaccine trial has begun in Mali with support from NIAID, aiming to prevent the deadliest form of malaria. The FMP-1 vaccine, developed by WRAIR and GSK Biologicals, will be tested on 40 adults for one year to assess its safety and efficacy.
The Southeast Regional Center of Excellence for Emerging Infections and Biodefense (SERCEB) will develop new vaccines and diagnostics for orthopoxviruses, Bacillus anthracis, and Y. pestis. The consortium aims to address difficult problems in emerging infections with unprecedented speed.
The Wyeth Pharmaceuticals team is being recognized for their role in developing the first combined pneumococcal vaccine for infants, Prevnar. The vaccine has dramatically advanced the health and well-being of children worldwide by preventing serious diseases such as meningitis, bacteremia, and pneumonia.
The US Army has awarded a $1 million grant to Virginia Tech researcher Thomas J. Inzana to develop a vaccine and diagnostic test for tularemia, also known as 'rabbit fever'. The goal is to create an effective vaccine that can stimulate the production of proteins that stimulate T-cells of the cellular immune system.
The trial, led by Saint Louis University, is a phase I trial investigating the safety and immune response of EP HIV-1090 vaccine candidate. Participants will receive the vaccine or placebo over 18 months, with observations to assess its potential effectiveness against HIV.
The St. Jude team successfully developed a custom-made vaccine against the H5N1 flu virus in just four weeks, thanks to a modified technique called reverse genetics. The vaccine was created by mixing genes from H5N1 with those from a common flu virus, making it safe for human use.
The Johns Hopkins Bloomberg School of Public Health has been awarded $30 million to develop and introduce a pneumococcal vaccine for children in the world's poorest countries. The Pneumococcal Accelerated Development and Introduction Plan (ADIP) team will work with international partners to address research, supply, and financing issue...
The Lancet discusses the conflict between scientific openness and global security concerns, highlighting the need for defensive biological research to prevent the spread of knowledge and dangerous materials. Pneumococcal vaccines are also reviewed, showing varying effectiveness in developed countries.
AVANT Immunotherapeutics awarded subcontract to develop oral combination vaccine against anthrax and plague using proprietary technologies. The vaccine aims to offer rapid, effective protection from multiple biological agents with a single dose, eliminating the need for protracted dosing regimens.
Researchers found that patients infected with one strain of HIV can develop superinfection with another strain, compromising treatment. Genetic analysis confirmed the presence of a second type of HIV in the patient's blood, indicating that superinfection is possible and poses unique challenges for vaccine development.
The Jordan Report 20th Anniversary outlines significant advancements in vaccine research for diseases like HIV/AIDS, tuberculosis, malaria, and bioterrorism threats. The report emphasizes the importance of vaccines in preventing illness and death from infectious diseases.
A new study reveals dispersin, a protein on the surface of E. coli bacteria, helps promote its ability to survive and spread in the gut. Dispersin is now being explored as a potential vaccine candidate due to its strong immune response-provoking properties.
A team of researchers at the University of Toronto has identified a protein and developed a prototype vaccine that shows promise in treating Sjögren syndrome. The vaccine was able to stop disease progression even after the condition had fully developed.
The HHS has awarded contracts to Avecia and VaxGen Inc. to develop a new anthrax vaccine that can provide immunity in three or fewer doses, reducing administration time. The vaccine will be produced using recombinant DNA technology and is expected to protect individuals from anthrax spores even if administered shortly after exposure.
The European Molecular Biology Laboratory highlights the potential for genomic research to combat tropical diseases. However, commercial interest in developing treatments has been limited, and it will be necessary to combine efforts from not-for-profit organizations and private funds to support research in developing countries.
The University of Maryland Biotechnology Institute has licensed its DNA Bactofection technology to Microscience, enabling the delivery of DNA vaccines for viral diseases and cancers. Microscience will use the technology to develop a range of DNA vaccines, including those for typhoid, travellers' diarrhea, and hepatitis B virus infection.
A new HIV vaccine candidate has shown promising results, targeting a shared characteristic of all HIV strains and generating antibodies that neutralize a wide range of isolates. The complex could serve as a useful model for HIV vaccine development, bringing researchers closer to their goal of developing an effective vaccine.
Researchers have pinpointed the cause of hepatitis A virulence by identifying two key genes, 2C and VP1/2A. The discovery may lead to the development of a live, attenuated HAV vaccine that could be more effective and affordable for widespread use.
A team of Los Alamos researchers suggests using a consensus sequence of the HIV-1 virus as a basis for vaccines, rather than geographically specific strains. This approach aims to target common vulnerabilities in multiple strains of the virus.
Researchers discovered that an inactivated chickenpox vaccine may prevent healthy elderly people from developing shingles and protect transplant recipients against viruses and bacteria. The vaccine boosted memory T cells to mount an attack during the transplant and recovery, reducing shingle risk.
A new pneumococcal vaccine has been shown to significantly reduce the incidence of pneumonia and invasive disease in children in Soweto, South Africa. The vaccine, which includes two additional strains of pneumococcus prevalent in developing countries, reduced pneumonia by over 20% and invasive disease by 50-80%.
A new vaccine targeting ticks' gut wall could significantly reduce their fertility and larval survival, decreasing the risk of diseases like Lyme disease and tick-borne encephalitis. The development comes as tick-borne diseases are increasing in the UK and becoming more prevalent globally.
The American Chemical Society is examining scientific connections between the US and Cuba, with a focus on fostering Cuban-American research partnerships. Cubans and scientists with Cuban connections will discuss topics such as chemical education and nanotechnology.
A University of Florida researcher has developed a feline AIDS vaccine that the federal government has approved for commercial use. The vaccine, expected to be available this summer, is based on viruses from long-term nonprogressor cats and may aid in human HIV development.
Researchers at Virginia Tech will develop plant-expressed antigens and adjuvants to create affordable, effective vaccines. The goal is to produce inexpensive, disease-fighting vaccines through plant-based delivery systems.